KLRS

SEC source: 0000899243-21-007331 · doc4.xml · nonDerivative · entry 1

Vera Juan · CIK 0001755495 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,447,910

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.90 to $39.85. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007842 · doc4.xml · nonDerivative · entry 2

Bornstein Jeffrey S · CIK 0001579989 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.21 to $41.275. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F2 · ownership.nature: Shares held by Whipstick Ventures, LLC. The Reporting Person has a controlling interest in Whipstick Ventures, LLC and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007842 · doc4.xml · nonDerivative · entry 1

Bornstein Jeffrey S · CIK 0001579989 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 812

F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.18 to $41.14. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F2 · ownership.nature: Shares held by Whipstick Ventures, LLC. The Reporting Person has a controlling interest in Whipstick Ventures, LLC and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 7

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,007,278

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 6

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,007,478

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.89 to $41.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 5

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,010,243

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.60 to $40.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 4

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,011,243

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.16 to $39.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 5

Vera Juan · CIK 0001755495 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,449,110

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.73 to $41.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 4

Vera Juan · CIK 0001755495 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,453,170

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.54 to $40.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 3

Vera Juan · CIK 0001755495 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,454,570

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.21 to $39.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007275 · doc4.xml · nonDerivative · entry 5

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,491,831

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.02 to $41.78. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007275 · doc4.xml · nonDerivative · entry 4

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,493,217

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.59 to $40.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007275 · doc4.xml · nonDerivative · entry 3

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,493,617

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.28 to $39.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 6

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 505,330

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

SEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 5

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 505,430

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.56 to $41.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 4

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 506,730

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.22 to $40.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 3

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,130

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.20 to $38.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007270 · doc4.xml · nonDerivative · entry 6

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,306

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020.

SEC source: 0000899243-21-007270 · doc4.xml · nonDerivative · entry 5

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,506

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020.

F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.43 to $41.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007270 · doc4.xml · nonDerivative · entry 4

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,806

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.22 to $39.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007270 · doc4.xml · nonDerivative · entry 3

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,026

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $38.16 to $39.00. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 1

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 490,134

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,012,443

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 2

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,012,543

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.10 to $42.64. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007278 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 1,013,543

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.10 to $42.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by Salt Free LP. The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 2

Vera Juan · CIK 0001755495 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,456,570

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.25 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007279 · doc4.xml · nonDerivative · entry 1

Vera Juan · CIK 0001755495 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,457,536

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 3, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.20 to $42.18. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007275 · doc4.xml · nonDerivative · entry 2

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,494,117

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.45 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007275 · doc4.xml · nonDerivative · entry 1

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,494,317

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.38 to $42.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 2

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 507,630

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.21 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007272 · doc4.xml · nonDerivative · entry 1

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 508,030

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.21 to $42.17. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007270 · doc4.xml · nonDerivative · entry 2

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,626

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $42.44 to $43.13. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-007270 · doc4.xml · nonDerivative · entry 1

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 68,926

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 6, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.35 to $42.32. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-004953 · doc4.xml · nonDerivative · entry 1

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 520,266

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-21-004952 · doc4.xml · nonDerivative · entry 1

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 510,730

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-21-003181 · doc4.xml · derivative · entry 5

Hallal David · CIK 0001457477 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 273,000

Underlying: Common Stock · 273,000 shares

Expires 2031-01-21

F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 21, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-003181 · doc4.xml · nonDerivative · entry 1

Hallal David · CIK 0001457477 · Director · Chief Executive Officer · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,230,666

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 21, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002768 · doc4.xml · derivative · entry 2

Atillasoy Ercem · CIK 0001818802 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common Stock · 52,000 shares

Expires 2031-01-19

F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002768 · doc4.xml · nonDerivative · entry 1

Atillasoy Ercem · CIK 0001818802 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,500

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002767 · doc4.xml · derivative · entry 2

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,250

Underlying: Common Stock · 81,250 shares

Expires 2031-01-19

F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002767 · doc4.xml · nonDerivative · entry 1

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 575,115

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002765 · doc4.xml · derivative · entry 3

Sinha Vikas · CIK 0001337845 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 109,200

Underlying: Common Stock · 109,200 shares

Expires 2031-01-19

F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002765 · doc4.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 865,407

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002764 · doc4.xml · derivative · entry 2

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,500

Underlying: Common Stock · 32,500 shares

Expires 2031-01-19

F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002764 · doc4.xml · nonDerivative · entry 1

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,676

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002762 · doc4.xml · derivative · entry 5

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common Stock · 52,000 shares

Expires 2031-01-19

F4 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002762 · doc4.xml · nonDerivative · entry 3

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,000

F2 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002758 · doc4.xml · derivative · entry 2

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2031-01-19

F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002758 · doc4.xml · nonDerivative · entry 1

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 559,640

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-002759 · doc4.xml · derivative · entry 4

Miller Edward · CIK 0001619252 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,000

Underlying: Common Stock · 52,000 shares

Expires 2031-01-19

F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 19, 2022, with the remainder vesting in twelve equal quarterly installments thereafter.